Japanese pharma’s neurology focus not going away

Globally, the devastating and widespread impact of neurological disorders like Alzheimer's disease, epilepsy, Parkinson’s disease and depression is only getting worse.

This is particularly true in the Asia-Pacific (APAC) region, where prevalence is high, and access to treatment depends to a large extent on geography.

"Japanese pharmaceutical companies are at the forefront of addressing these challenges, leveraging their expertise, resources, and commitment to innovation"Indeed, the World Health Organization stated in March 2024 that more than 80% of deaths and health losses caused by neurological disorders occur in low- and middle-income countries, and access to treatment varies widely.